Abstract No. 182: Quality of life assessment of patients treated with Yttrium-90 or transarterial chemoembolization: A comparative study using the fact-hep

Chemoembolization and Radioembolization for Hepatocellular Carcinoma

“…First, although the concept of segmental injections in HCC is the standard for most embolotherapies, radioembolization, with an improved toxicity profile, appears to play a role in more advanced disease 40–42 . This includes patients with performance status 1–2, multifocal disease with or without PVT.…”

“…Since segmental injections are not mandated, lobar infusions treating larger territory of disease is routine 43 . Second, while cTACE/DEB-TACE requires inpatient hospitalization, radioembolization has shifted the embolotherapy paradigm into one of outpatient therapies, translating in better quality-of-life 41, 42 . Finally, in contradistinction to routine, scheduled embolizations with cTACE/DEB-TACE, radioembolization patients receive 1 treatment, with follow-up sessions on an as-needed basis.…”

Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives

“…These challenges were confirmed in a prospective phase II study comparing TACE and 90 Y using quality-of-life metrics. The study demonstrated that despite 54 by validated quality-of-life measures.…”

“…These challenges were confirmed in a prospective phase II study comparing TACE and 90 Y using quality‐of‐life metrics. The study demonstrated that despite enrolling more‐advanced patients (larger tumors, performance status 1‐2) to 90 Y, 90 Y outperformed TACE (small tumors, segmental injections) by validated quality‐of‐life measures.…”

“…90 Y in BCLC A is suggested, in part, by higher CPN, compared to TACE, and by the innovative concepts of segmentectomy and lobectomy (permitting resection) and downstaging (permitting transplantation) . For BCLC B, comparative studies are also complex, because inherent quality‐of‐life differences, long natural history, as well as complications of crossover at progression, result in unachievable 1,000‐patient trial designs . Finally, in BCLC C, the dramatic effect on PVT (not observed with TACE) provides strong rationale for (combinations with and comparisons) to sorafenib .…”